Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2TMB-H 1Recurrence 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 60Cisplatin 38Oxaliplatin 30Capecitabine 28Fluorouracil 21Leucovorin 19pembrolizumab 11Irinotecan 11durvalumab 9130-nm albumin-bound paclitaxel 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Platinum 6Magnetic Resonance Spectroscopy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 5Specimen Handling 5Sorafenib 5Radiotherapy 5Carboplatin 5Docetaxel 4Biopsy 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Paclitaxel 3Lapatinib 3Interleukin-12 Subunit p35 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gallbladder Neoplasms × IMC-001 × Clear all
NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Sorrento Therapeutics, Inc.

Phase 2 Withdrawn
GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡